WASHINGTON — The Trump administration claims its newest plan to cap insulin copays could solve seniors’ woes with the high cost of insulin. But the reality is more complicated.
The plan, which was released Wednesday, would allow certain private Medicare plans to cap how much seniors can spend for insulin at $35 a month. It’s a politically popular policy being rolled out just as high insulin costs are dominating the conversation over high health care costs more generally.
But there are open questions about the true impact of Trump’s plan. Are insulin costs really an issue for seniors? And how many seniors would Trump’s plan impact?
About the Author Reprints
